Skip to main content
SpringerLink
Log in

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate the new synthetic HMG-CoA reductase inhibitor, fluvastatin, for efficacy, safety and tolerability in comparison to cholestyramine. One hundred fifty one primary hypercholesterolaemic patients participated in this double-blind, parallel-group, randomized study. During the first 12 weeks of the study, fluvastatin (20 mg and 40 mg daily) was compared with cholestyramine (16 g per day). In the subsequent, 6-week part of the study, the comparative efficacy, safety and tolerability of 20 mg fluvastatin, combined with cholestyramine (4 g, 8 g, or 16 g) were assessed.

Fluvastatin (40 mg) reduced LDL cholesterol by 28.0%, triglycerides by 10.5% and increased HDL cholesterol by 3.7%. Cholestyramine (16 g) reduced LDL cholesterol by 35.0%, but raised triglycerides and HDL cholesterol by 12.3% (p<0.01) and 3.7% respectively.

The combination of fluvastatin 20 mg and cholesty-ramine (4 g, 8 g and 16 g) induced the following reductions in LDL cholesterol: 30.4%, 35.6% and 46.6% respectively. There was no significant change in triglycerides in either group although HDL cholesterol was raised by 4.9%, 8.3% and 7.2% respectively. One patient treated with fluvastatin and two treated with cholesty-ramine were withdrawn from the study due to elevation of liver transaminases. The most frequent subjective adverse effects in both treatment groups were mild, transient gastrointestinal complaints.

Thus, fluvastatin was effective as a lipid-lowering agent; the effect was further enhanced when fluvastatin was combined with cholestyramine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR (1990) Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter group I. Arch Intern Med 150: 341–345

    Google Scholar 

  2. Wiklund O, Angelin B, Fager G, Erikson M, Olofsson SO, Berglund L, Linden T, Sjøberg A, Bondjers G (1990) Treatment of familial hypercholesterolemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 228: 241–247

    Google Scholar 

  3. Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef A F, Birkenhager J C (1990) The efficacy and safety of pravastatin, compared to and in combination with bile acid resins in familial hypercholesterolemia. J Intern Med 228: 201–205

    Google Scholar 

  4. Havel RJ, Hunninghake DB, Illingworth DR, Lees S, Stein E, Tobert A, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, Lees AM, Leon AS, Gardner K, Johnson G, Mellies MJ, Rhymer PA, Tun P (1987) Lovastatin (mevinolin) in the treatment of heterozygous hypercholesterolemia. Ann Intern Med 107: 609–615

    Google Scholar 

  5. Lovastatin Study Group II (1986) Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. J Am Med Assoc 256: 2829–2834

    Google Scholar 

  6. Gemershausen JL, Hunt VM, Bostedor RG, Baily PJ, Karkas JD, Alberts JD (1989) Tissue selectivity of the cholesterol lowering agents, lovastatin, simvastatin and pravastatin in rats in vivo Biochem Biophys Res Commun 158: 667–675

    Google Scholar 

  7. Catalano PM, Masonson HN, Newman TJ, Alexander JC (1989) Clinical safety of pravastatin. In: La Rosa JC (ed) Focus on pravastatin. (Royal Society of Medicine Services international congress and symposium series no. 162) Royal Society of Medicine Services Ltd., London, pp 35–38

    Google Scholar 

  8. LaRosa JC (1989) Pravastatin: a new hydrophilic HMG-CoA-reductase inhibitor. In: La Rosa JC(ed) Focus on pravastatin. (Royal Society of Medicine Services international congress and symposium series no. 162) Royal Society of Medicine Services Ltd., London, pp 39–43

    Google Scholar 

  9. Levy RI, Fredricson DS, Stone NJ, Bilheimer DW, Brown VW, Glueck CJ, Gotto AM, Herbert PN, Kwiterovich PO, Langer T, LaRosa J, Lux SE, Rider AK, Schulman AS, Sloan HR (1973) Cholestyramine in type II hyperlipidemia. Ann Intern Med 79: 51–58

    Google Scholar 

  10. Study Group, European Atherosclerosis Society (1988) The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 9: 571–600

    Google Scholar 

  11. Vu Dac N, Mezdour H, Parra J, Luc G, Luyeye I, Fruchart JC (1989) A selective bi-site immunoenzymatic procedure for human Lp(a) lipoprotein quantification using monoclonal antibodies against apo [a] apo B. J Lipid Res 30: 1437–1443

    Google Scholar 

  12. Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. J Am Med Assoc 251: 351–364

    Google Scholar 

  13. Einarson K, Ericsson S, Ewerth S, Reihner E, Rudlin M, St»hlberg D, Angelin B (1991) Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 40 [Suppl 1]: S53-S58

    Google Scholar 

  14. Illingworth D (1991) HMG CoA reductase inhibitor. Curr Opin Lipid 2: 24–30

    Google Scholar 

  15. Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of of apo B-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 31: 567–582

    Google Scholar 

  16. Malmiender CL, Lonthie JF, Delacroix C, Magot T (1989) Effects of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 80: 101–109

    Google Scholar 

  17. Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apoprotein B-containing lipoproteins. J Intern Med 227: 81–94

    Google Scholar 

  18. Mabuchi H, Sakai T, Sakay Y, Yoshimura A, Watanabe A, Wakasugi T, Koisumi J, Takeda R (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effect of compactin and cholestyramine. N Engl J Med 308: 609–613

    Google Scholar 

  19. Avogaro P, Bon GB, Cazzolato G, Quinci GB (1979) Are apoproteins better discriminators than lipids for atherosclerosis? Lancet I: 901–903

    Google Scholar 

  20. Ditschuneit HH, Kuhn K, Ditschuneit H (1991) Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 40 [Suppl 1] S27-S32

    Google Scholar 

  21. Levy RI, Troendle A, Fattu JM (1993) Drug treatment of dyslipoproteinemia: a quarter century of progress. Circulation 87 [Suppl III]: III45-III53

    Google Scholar 

  22. Livingstsone MB, Prentice AM, Strain JJ, Coward WA, Black AE, Barker ME, McKenna PG, Withhead RG (1990) Accuracy of weighed dietary records in studies of diet and health. BMJ 300: 1138–1139

    Google Scholar 

  23. Scholler DA (1990) How accurate is self reported dietary energy intake? Nutr Rev 48: 373–379

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid Clinic, Medical Department A, National Hospital, Oslo, Norway

    E. Hagen, H. Istad, L. Ose, H. -M. Eriksen & V. Selvig

  2. Medinnova, National Hospital, Oslo, Norway

    E. Bodd

  3. SERLIA, Institute-Pasteur, Lille, France

    J. M. Bard & J. C. Fruchart

  4. Sandoz Pharma AG, Oslo, Norway

    M. Borge

  5. Sandoz Pharma Ltd., Basle, Switzerland

    M. -C. Wolf & P. Pfister

Authors
  1. E. Hagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Istad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Ose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Bodd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. -M. Eriksen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Selvig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Bard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. C. Fruchart
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Borge
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. -C. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagen, E., Istad, H., Ose, L. et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 46, 445–449 (1994). https://doi.org/10.1007/BF00191909

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00191909

Key words

Search

Navigation